For validation of asthma drug and device products, VIDA provides unmatched imaging core lab services. With its ISO 13485 certified service and extensively validated biomarkers, clinical trial partners can trust they are receiving the highest quality data available, leading to faster go/no-go decisions, shorter trials, better patient selection criteria, and a clearer understanding of the mechanism of action for their treatment.
Exclusive Imaging Software for SARP
VIDA is utilized by the Severe Asthma Research Program–the world’s most comprehensive severe asthma study
Validated Biomarkers
VIDA’s airway analysis is second to none, with 13 proven quantitative biomarkers relevant to asthma.
Global Capabilities
VIDA provides services for clients in 30 counties and in 8 languages.
Enhancing Outcomes with Precision
VIDA provides precise biomarkers for phenyotyping asthma subtypes and detects positive responses to pharmacological and device treatments1-3.
Superior Quality
VIDA’s software is FDA, CE, TGA, and CMDCAS certified. VIDA’s process has been proven and refined for 10+ years and is ISO certified.
CT Protocol Expertise
VIDA leads the way in CT Protocols, maximizing image quality while minimizing radiation dose.
1- Trivedi A, Hall C, Hoffman EA, Woods JC, Gierada DS, Castro M. Using Imaging as a Biomarker for Asthma. The Journal of Allergy and Clinical Immunology. 2017;139(1):1-10.
2. Choi S, Hoffman EA, Wenzel SE, et al. Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes. J Allergy Clin Immunol. 2017.
3. Brightling CE, Nordenmark LH, Jain M, et al. Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma. American journal of respiratory and critical care medicine. 2016;194(1):118-120.